Ambryon Biosciences

Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma

Phase 2 single-arm trial (KarMMa) of idecabtagene vicleucel (ide-cel, bb2121), an anti-BCMA CAR T-cell therapy, in 137 treated patients with triple-class exposed relapsed and refractory multiple myeloma. Overall response rate was 74.5% (34.3% complete response).

StatusCompleted
PhasePhase 2
Primary Endpoint ResultInconclusive
Enrollment149
Start Date2017-12-13
Primary Completion Date2023-12-20

Results Summary

In the 137 treated patients (ClinicalTrials.gov posted results, follow-up up to about 5 years), the overall response rate (partial response or better, independent committee) was 74.5% (95% CI 67.1-81.8) and the complete or stringent complete response rate was 34.3% (26.4-42.3). In 102 responders, median time to response was 1.0 month and median duration of response was 11.04 months (9.92-12.52). Median progression-free survival was 8.90 months (6.01-11.86) and median overall survival was 28.25 months (20.21-38.08). MRD negativity at 10^-5 with at least very good partial response was 40.9% (32.6-49.6). Grade 3 or 4 adverse events occurred in 136 of 137 patients; cytokine release syndrome in 116 (serious in 22 of 137; non-serious in 110 of 137), neurotoxicity in 53 and infections in 95. Serious adverse events occurred in 108 of 137 (adverse-event table); 82 of 137 died.

Design Implications

A single infusion of autologous anti-BCMA CAR T cells after lymphodepletion produces responses in most heavily pretreated myeloma patients, but few are durable: median duration of response was about 11 months and median progression-free survival 8.9 months, so BCMA targeting alone needs a way to extend CAR T-cell persistence or prevent relapse. Antigen loss is one escape route: a KarMMa participant relapsed with a clone carrying a homozygous deletion of the BCMA gene (TNFRSF17), which argues for a second target or screening for BCMA loss. Higher CAR T-cell exposure was associated with higher response rates, but exposure overlapped widely across the 150, 300 and 450 × 10^6 dose levels, so dose is a weak control of expansion. Cytokine release syndrome (116 of 137), neurotoxicity (53), prolonged cytopenias and infections are the main liabilities to design against.

Rationale

Idecabtagene vicleucel (ide-cel, bb2121) is made from the patient's own T cells, transduced with a lentiviral vector that encodes a chimeric antigen receptor (CAR) against B-cell maturation antigen (BCMA, TNFRSF17), and given as one intravenous infusion of up to 450 × 10^6 CAR+ T cells after fludarabine and cyclophosphamide lymphodepletion. BCMA is expressed mainly on plasma cells and late B cells, including myeloma cells. The CAR lets T cells recognize BCMA without HLA restriction, expand and kill myeloma cells that no longer respond to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibodies.

Limitations

Single-arm, open-label phase 2 with no control arm; 137 of 149 enrolled patients were treated and response rates use the treated patients as denominator. No success criterion for the overall response rate appears in the sources used (posted results and abstracts of secondary analyses; no results paper is linked in the registry), so the primary endpoint is not judged. Counts differ between registry tables (serious adverse events 98 in the safety outcome, 108 in the adverse-event table).

Registry record

This is an open label, single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma. A leukapheresis procedure will be performed to manufacture bb2121 chimeric antigen receptor (CAR) modified T cells. Prior to bb2121 infusion subjects will receive lymphodepleting therapy with fludarabine and cyclophosphamide.

Primary OutcomesOverall Response Rate
KeywordsMultiple Myeloma, Efficacy and Safety, BB2121, CAR T Cell, BCMA, Relapsed and Refractory
Registry Last Updated2025-05-23
Results First Posted Date2025-05-23
Minimum Age18 Years
Modalitiescell_therapy
Intervention Namesbb2121
AllocationNot Applicable
MaskingNone
Primary PurposeTreatment
Has ResultsYes
AcronymKarMMa
Enrollment TypeActual
CountriesUnited States, Belgium, Canada, France, Germany, Italy, Japan, Spain
Intervention Typesbiological
Study TypeInterventional
Intervention ModelSingle Group
Healthy VolunteersNo
Condition TermsMultiple Myeloma, Recurrence
Completion Date2023-12-20
Lead Sponsor ClassIndustry
Eligibility SexAll

Official Title

A Phase 2, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma

Eligibility Criteria

Inclusion Criteria:

Eligibility is determined prior to leukapheresis. Subjects must satisfy the following criteria to be enrolled in the study:

  1. Subject is ≥ 18 years of age at the time of signing the informed consent form (ICF).

  2. Documented diagnosis of multiple myeloma

    • Must have received at least 3 prior MM treatment regimens. Note: induction with or without hematopoietic stem cell transplant and with or without maintenance therapy is considered a single regimen.
    • Must have undergone at least 2 consecutive cycles of treatment for each regimen, unless PD was the best response to the regimen.
    • Must have received a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody.
    • Must be refractory to the last treatment regimen.
  3. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

  4. Subjects must have measurable disease, including at least one of the criteria below:

    • Serum M-protein greater or equal to 1.0 g/dL
    • Urine M-protein greater or equal to 200 mg/24 h
    • Serum free light chain (FLC) assay: involved FLC level greater or equal to 10 mg/dL (100 mg/L) provided serum FLC ratio is abnormal
  5. Recovery to Grade 1 or baseline of any non-hematologic toxicities due to prior treatments, excluding alopecia and Grade 2 neuropathy.

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment:

  1. Subjects with known central nervous system involvement with myeloma.
  2. History or presence of clinically relevant central nervous system (CNS) pathology.
  3. Subjects with active or history of plasma cell leukemia.
  4. Subjects with solitary plasmacytomas or non-secretory myeloma without other evidence of measurable disease
  5. Inadequate organ function
  6. Ongoing treatment with chronic immunosuppressants
  7. Previous history of an allogeneic hematopoietic stem cell transplantation or treatment with any gene therapy-based therapeutic for cancer or investigational cellular therapy for cancer or BCMA targeted therapy
  8. Evidence of human immunodeficiency virus (HIV) infection.
  9. Seropositive for and with evidence of active viral infection with hepatitis B virus (HBV)
  10. Seropositive for and with evidence of active viral infection with hepatitis B virus (HBV) and Hepatitis C virus (HCV)
  11. Subjects with a history of class III or IV congestive heart failure (CHF) or severe non-ischemic cardiomyopathy, history of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months.
  12. Subjects with second malignancies in addition to myeloma if the second malignancy has required therapy in the last 3 years or is not in complete remission
  13. Pregnant or lactating women.
  14. Subject with known hypersensitivity to any component of bb2121 productThe presence of any of the following will exclude a subject from enrollment:

1. Subjects with known central nervous system involvement with myeloma. 2. History or presence of clinically relevant central nervous system (CNS) pathology.

3. Subjects with active or history of plasma cell leukemia. 4. Subjects with solitary plasmacytomas or non-secretory myeloma without other evidence of measurable disease 5. Inadequate organ function 6. Ongoing treatment with chronic immunosuppressants 7. Previous history of an allogeneic hematopoietic stem cell transplantation or treatment with any gene therapy-based therapeutic for cancer or investigational cellular therapy for cancer or BCMA targeted therapy 8. Evidence of human immunodeficiency virus (HIV) infection. 9. Seropositive for and with evidence of active viral infection with hepatitis B virus (HBV) and Hepatitis C virus (HCV) 10. Subjects with a history of class III or IV congestive heart failure (CHF) or severe non-ischemic cardiomyopathy, history of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months. 11. Subjects with second malignancies in addition to myeloma if the second malignancy has required therapy in the last 3 years or is not in complete remission 12. Pregnant or lactating women. 13 Subject with known hypersensitivity to any component of bb2121 product, cyclophosphamide, fludarabine, or tocilizumab.

Identifiers & revision